PAB
Patrys Limited
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
2
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Patrys Ltd. engages in the commercialisation of the group's proprietary technologies to develop natural human antibody-based therapeutic products for the treatment of cancer and the pursuit of non-dilutive funding sources. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2007-07-13. The firm focuses on the development of antibody therapies for the treatment of cancer. The company is engaged in developing the treatment of Glioblastoma (GBM) and Triple Negative Breast Cancer (TNBC). The firm has developed two forms of deoxymab 3E10, including PAX-DX1 and PAT-DX3. The 3E10 antibody has several unusual biological properties not typically seen in antibodies, such as cancer targeting, blood-brain barrier, cell penetrating and inhibit deoxyribonucleic acid (DNA) damage repair. The firm has developed two forms of deoxymab 3E10, including PAX-DX1 and PAT-DX3. The company also uses the PAT-DX1 antibody to deliver nanoparticles carrying therapeutic payloads to the inside of cells. The firm is in the process of the first human clinical trial of PAT-DX1. Its two product candidates, PAT-DX2 and PAT-DX1-NP are under preclinical stage.
📈 Performance
Price History
-68.44%
1M
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.01
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in PAB
2
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in PAB
1286 days
PAB investor breakdown
💵 Income of investors
More than 200k
150k - 200k
50%
100k - 150k
50k - 100k
50%
Less than 50k
👶 Age of investors
18 - 25
26 - 34
50%
35 - 90
50%
🙋 Legal gender of investors
Female
Male
100%
Pearlers who invest in PAB also invest in...
Archer Materials Ltd. is a materials technology company developing advanced semiconductor devices and processor chips related to quantum computing and medical diagnostics in Australia. The company is headquartered in Adelaide, South Australia. The company went IPO on 2007-08-14. The firm is developing advanced semiconductor devices, including chips relevant to quantum computing and medical diagnostics. The firm is progressing the development of its 12CQ quantum computing qubit processor chip (12CQ chip) and lab-on-a-chip biochip technology (biochip). The 12CQ chip is utilizing a carbon-based architecture that has the potential for practical qubit processing. The company is focused on advancing its 12CQ chip technology towards integration with mobile devices. Its biochip development involves integrating graphene with miniaturized lab-on-a-chip platforms for advanced medical diagnostics. The company is designing and building its biochip in clean-room facilities and engineering materials at the atom-scale. The company also develops its biochip for digitizing biologically relevant signals like those from viruses or bacteria.
📊 Share price
$0.47 AUD
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
📊 Share price
$104.08 AUD
NULL GLOBAL
NULL EX AUSTRALIA
NULL BETA
FAIR.AX was created on 2017-11-27 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes Australian companies that have passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.
📊 Share price
$18.55 AUD
NULL AUSTRALIA
NULL NEW ZEALAND
NULL ETHICAL
NULL THEMATIC
NULL SUSTAINABLE
A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 2975.21m in AUM and 200 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.
📊 Share price
$120.79 AUD
NULL AUSTRALIA
NULL BETA
ETHI.AX was created on 2017-01-05 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes a portfolio of large global stocks identified as Climate Leaders that have also passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.
📊 Share price
$12.45 AUD
NULL GLOBAL
NULL SMART BETA
NULL ETHICAL
NULL EX AUSTRALIA
Want more shares? Try these...
